As shown in Figures 9G,H below, the response rate of anti-PD-L1 therapy in the high-m6aRiskscore group (26%) was higher than that in the low-m6aRiskscore group (20%) in urothelial carcinoma (Figure 9G). Here, CD274 is linked to urothelial carcinoma.